EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer

Ke Li, Wei Liu, Hang Yu, Jiwei Chen, Wenxuan Tang, Jianpeng Wang, Ming Qi, Yuyun Sun, Xiaoping Xu, Ji Zhang, Xinxiang Li, Weijian Guo und 3 weitere

Journal of Clinical Investigation · 15.02.2024 · 134 (4)

DOI: 10.1172/jci170490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 04.01.2024. Verfasst von Ke Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Colonic Neoplasms, Antibodies, Bispecific, Quinolines. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUNDImproving and predicting tumor response to immunotherapy remains challenging. Combination therapy with a transforming growth factor-β receptor (TGF-βR) inhibitor that targets cancer-associated fibroblasts (CAFs) is promising for the enhancement of efficacy of immunotherapies. However, the effect of this approach in clinical trials is limited, requiring in vivo methods to better assess tumor responses to combination therapy.METHODSWe measured CAFs in vivo using the 68Ga-labeled fibroblast activation protein inhibitor-04 (68Ga-FAPI-04) for PET/CT imaging to guide the combination of TGF-β inhibition and immunotherapy. One hundred thirty-one patients with metastatic colorectal cancer (CRC) underwent 68Ga-FAPI and 18F-fluorodeoxyglucose (18F-FDG) PET/CT imaging. The relationship between uptake of 68Ga-FAPI and tumor immunity was analyzed in patients. Mouse cohorts of metastatic CRC were treated with the TGF-βR inhibitor combined with KN046, which blocks programmed death ligand 1 (PD-L1) and CTLA-4, followed by 68Ga-FAPI and 18F-FDG micro-PET/CT imaging to assess tumor responses.RESULTSPatients with metastatic CRC demonstrated high uptake rates of 68Ga-FAPI, along with suppressive tumor immunity and poor prognosis. The TGF-βR inhibitor enhanced tumor-infiltrating T cells and significantly sensitized metastatic CRC to KN046. 68Ga-FAPI PET/CT imaging accurately monitored the dynamic changes of CAFs and tumor response to combined the TGF-βR inhibitor with immunotherapy.CONCLUSION68Ga-FAPI PET/CT imaging is powerful in assessing tumor immunity and the response to immunotherapy in metastatic CRC. This study supports future clinical application of 68Ga-FAPI PET/CT to guide precise TGF-β inhibition plus immunotherapy in CRC patients, recommending 68Ga-FAPI and 18F-FDG dual PET/CT for CRC management.TRIAL REGISTRATIONCFFSTS Trial, ChiCTR2100053984, Chinese Clinical Trial Registry.FUNDINGNational Natural Science Foundation of China (82072695, 32270767, 82272035, 81972260).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsAntibodies, BispecificQuinolinesHumansAnimalsMiceReceptors, Transforming Growth Factor betaPositron Emission Tomography Computed TomographyFluorodeoxyglucose F18Positron-Emission TomographyImmunotherapyTransforming Growth Factor beta

Stichwörter der Autor:innen

Cancer immunotherapyColorectal cancerDiagnostic imagingGastroenterologyOncology

Substanzen

Receptors, Transforming Growth Factor beta68Ga-FAPIFluorodeoxyglucose F18Antibodies, BispecificTransforming Growth Factor betaQuinolines

Autor:innen und Institutionen

  • Cancer Institute, Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Center for Biomedical Imaging, Fudan University, Shanghai, China.
  • Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.
  • Department of Oncology and.
  • School of Clinical Medicine, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Li, K., Liu, W., Yu, H., Chen, J., Tang, W., Wang, J., Qi, M., Sun, Y., Xu, X., Zhang, J., Li, X., Guo, W., Li, X., Song, S., & Tang, S. (2024). 68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer. Journal of Clinical Investigation, 134(4). https://doi.org/10.1172/jci170490

Vancouver

Li K, Liu W, Yu H, Chen J, Tang W, Wang J, et al. 68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer. Journal of Clinical Investigation. 2024;134(4). doi:10.1172/jci170490

BibTeX
@article{Li2024,
  author = {Li, Ke and Liu, Wei and Yu, Hang and Chen, Jiwei and Tang, Wenxuan and Wang, Jianpeng and Qi, Ming and Sun, Yuyun and Xu, Xiaoping and Zhang, Ji and Li, Xinxiang and Guo, Weijian and Li, Xiaoling and Song, Shaoli and Tang, Shuang},
  title = {68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {4},
  doi = {10.1172/jci170490}
}
Kostenlos starten →